stockrow
Saturday 7 November 2026
Export AGEN’s income statement to Excel — free account
Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024.
- Revenue
- +4.14%
- EPS
- −99.0%
- Free cash flow
- −37.1%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
7.13
0.69
+10.71%
Follow AGEN
Alert me
Agenus Inc. (AGEN) P/E ratio
As of 6 November 2026, Agenus Inc. (AGEN) trades at a P/E ratio of 10.7×. Over the past ten years it has ranged from 0.0× (March 2026) to 22.0× (August 2022); the current reading is higher than 98% of that period. That is in line with the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 14.9× | 1,188.87% |
| Jun 2026 | 1.2× | (42.53%) |
| Mar 2026 | 2.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 22.0×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| BNTC Benitec Biopharma Limited compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| AGEN Agenus Inc. | 10.7× |
| SCTX Scribe Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)